Anita Raghuwanshi, MD
Endocrinology, Diabetes & Metabolism · Cape May Court House, NJNPI 1669630109
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.3%. 2025 is the largest year on record at $5,511, 8.3 times the $664 reported in 2019.
Across 225 payments — averaging $62.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- Madrigal Pharmaceuticals$3K
- Abbott$2K
- Insulet Corporation$2K
- Tandem Diabetes Care, Inc.$2K
- Novo Nordisk$897
- plus $1K from 16 others
What the payments were for
- Consulting fees$3,15022%
- Speaking & faculty fees$3,07022%
- Travel & lodging$2,38917%
- Food & beverage$5,38338%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 4 | $3,284 |
| Madrigal Pharmaceuticals | 3 | $3,166 |
| Abbott | 150 | $1,977 |
| Insulet Corporation | 14 | $1,712 |
| Tandem Diabetes Care, Inc. | 2 | $1,600 |
| Novo Nordisk | 12 | $897 |
| AstraZeneca(2 entities) | 7 | $425 |
| Boehringer Ingelheim | 5 | $305 |
| Medtronic | 2 | $188 |
| Amgen | 4 | $108 |
| Lilly USA, LLC | 4 | $102 |
| BETA Bionics, Inc. | 1 | $75 |
| Corcept Therapeutics | 4 | $62 |
| Dexcom, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $42 |
| Pfizer | 2 | $28 |
| Johnson & Johnson | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $19 |
| AbbVie | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$3,150
- t:slim X2 Insulin Pump with Control-IQ$1,600
- Omnipod$1,524
- FARXIGA$374
- Ozempic$242
- MINIMED 780G$173
- Saxenda$125
- RYBELSUS$124
- JARDIANCE$124
- Wegovy$114
How this compares
$14,119 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 409 | $795,547 |
| JardianceEmpagliflozin | 435 | $565,276 |
| MounjaroTirzepatide | 199 | $336,165 |
| FarxigaDapagliflozin Propanediol | 182 | $227,118 |
| TrulicityDulaglutide | 137 | $221,684 |
| JanuviaSitagliptin Phosphate | 162 | $184,242 |
| RybelsusSemaglutide | 80 | $140,855 |
| Bydureon BciseExenatide Microspheres | 78 | $119,201 |
| InvokanaCanagliflozin | 53 | $84,923 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $80,124 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 52 | $75,332 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 62 | $65,313 |
| Tresiba Flextouch U-100Insulin Degludec | 84 | $47,039 |
| Victoza 3-PakLiraglutide | 35 | $46,850 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 24 | $43,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $897 | $989,344541 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi | $305 | $660,337495 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humatrope | $102 | $585,976396 claims |
| AstraZenecaFarxiga | $425 | $227,118182 claims |
| Johnson & JohnsonInvokana | $21 | $84,92353 claims |
| AmgenProlia | $108 | $37,28722 claims |
| AbbVieSynthroid | $18 | $31,644318 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,284 | $25,23416 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $10,192802 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Cape May Court House
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.